Publikasi Scopus 2024 per tanggal 31 Januari 2024 (57 artikel)

Safari D.; Daningrat W.O.D.; Milucky J.L.; Khoeri M.M.; Paramaiswari W.T.; Tafroji W.; Salsabila K.; Winarti Y.; Soebandrio A.; Hadinegoro S.R.; Prayitno A.; Childs L.; Pimenta F.C.; Carvalho M.D.G.; Pilishvili T.
Safari, Dodi (23493586700); Daningrat, Wa Ode Dwi (57254035500); Milucky, Jennifer L. (57191839487); Khoeri, Miftahuddin Majid (55994827400); Paramaiswari, Wisiva Tofriska (57221097580); Tafroji, Wisnu (57118271600); Salsabila, Korrie (57192272141); Winarti, Yayah (57226141883); Soebandrio, Amin (8602893200); Hadinegoro, Sri Rezeki (56893685800); Prayitno, Ari (57193342301); Childs, Lana (57192371231); Pimenta, Fabiana C. (6603696480); Carvalho, Maria da Gloria (35496709400); Pilishvili, Tamara
23493586700; 57254035500; 57191839487; 55994827400; 57221097580; 57118271600; 57192272141; 57226141883; 8602893200; 56893685800; 57193342301; 57192371231; 6603696480; 35496709400; 35596106000
Nasopharyngeal carriage of Streptococcus pneumoniae among children <5 years of age in Indonesia prior to pneumococcal conjugate vaccine introduction
2024
PLoS ONE
19
1 January
e0297041
0
Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Centre for Genomic Pathogen Surveillance, Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; CDC Foundation, Atlanta, GA, United States; Medical and Clinical Affairs, US GSK Vaccines, GSK, Philadelphia, PA, United States
Safari D., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Daningrat W.O.D., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia, Centre for Genomic Pathogen Surveillance, Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Milucky J.L., National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Khoeri M.M., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Paramaiswari W.T., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Tafroji W., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Salsabila K., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Winarti Y., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Soebandrio A., Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia; Hadinegoro S.R., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Prayitno A., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Childs L., CDC Foundation, Atlanta, GA, United States; Pimenta F.C., National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Carvalho M.D.G., National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Pilishvili T., National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States, Medical and Clinical Affairs, US GSK Vaccines, GSK, Philadelphia, PA, United States
Pneumococcal conjugate vaccines (PCVs) prevent nasopharyngeal colonization with vaccine serotypes of Streptococcus pneumoniae, leading to reduced transmission of pneumococci and stronger population-level impact of PCVs. In 2017 we conducted a cross-sectional pneumococcal carriage study in Indonesia among children aged <5 years before 13-valent PCV (PCV13) introduction. Nasopharyngeal swabs were collected during visits to community integrated health service posts at one peri-urban and one rural study site. Specimens were analyzed by culture, and isolates were serotyped using sequential multiplex polymerase chain and Quellung reaction. Antibiotic susceptibility was performed by broth microdilution method. We enrolled 1,007 children in Gunungkidul District, Yogyakarta (peri-urban) and 815 in Southwest Sumba, East Nusa Tenggara (rural). Pneumococcal carriage prevalence was 30.9% in Gunungkidul and 87.6% in Southwest Sumba (combined: 56.3%). PCV13 serotypes (VT) carriage was 15.0% in Gunungkidul and 52.6% in Southwest Sumba (combined: 31.8%). Among pneumococcal isolates identified, the most common VT were 6B (16.4%), 19F (15.8%), and 3 (4.6%) in Gunungkidul (N = 323) and 6B (17.6%), 19F (11.0%), and 23F (9.3%) in Southwest Sumba (N = 784). Factors associated with pneumococcal carriage were age (1–2 years adjusted odds ratio (aOR) 1.9, 95% CI 1.4–2.5; 3–4 years aOR 1.5, 95% CI 1.1–2.1; reference <1 year), other children <5 years old in the household (aOR 1.5, 95% CI 1.1–2.0), and presence of ≥1 respiratory illness symptom (aOR 1.8, 95% CI 1.4–2.2). Overall, 61.5% of the pneumococcal isolates were non-susceptible to ≥1 antibiotic class and 13.2% were multi-drug non-susceptible (MDNS) (non-susceptible to ≥3 classes of antibiotics). Among 602 VT isolates, 73.9% were non-susceptible and 19.9% were MDNS. These findings are critical to establish a pre-PCV13 carriage prevalence and demonstrate the complexity in evaluating the impact of PCV13 introduction in Indonesia given the wide variability in the carriage prevalence as shown by the two study sites. Copyright: This is an open access article,
Anti-Bacterial Agents; Carrier State; Child; Child, Preschool; Cross-Sectional Studies; Humans; Indonesia; Infant; Nasopharynx; Pneumococcal Infections; Pneumococcal Vaccines; Serogroup; Streptococcus pneumoniae; Vaccines, Conjugate; amoxicillin plus clavulanic acid; antibiotic agent; azithromycin; cefepime; cefotaxime; ceftriaxone; cefuroxime; chloramphenicol; clindamycin; cotrimoxazole; ertapenem; erythromycin; fuel; kerosene; levofloxacin; linezolid; liquefied petroleum gas; macrolide; meropenem; moxifloxacin; natural gas; penicillin derivative; Pneumococcus vaccine; tetracycline; vancomycin; antiinfective agent; conjugate vaccine; Pneumococcus vaccine; antibiotic sensitivity; Article; bacterium isolate; broth dilution; child; coughing; cross-sectional study; dyspnea; female; fever; gen
U.S. Department of Health and Human Services, HHS; Centers for Disease Control and Prevention, CDC
Funding: This work was funded by the Grant or Cooperative Agreement Number, NU2GGH001852-03, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. The funders had no role in the study desi
Public Library of Science
19326203
38206916
Article
Q1
885
5108